Enhancement of renal function by a long-acting somatostatin analogue in patients with decompensated cirrhosis.
The effect of the long-acting somatostatin analogue SMS 201-995 on renal function was investigated in nine cirrhotic patients with ascites, low urine output, low serum sodium, and normal serum creatinine. SMS 201-995, infused at 40 micrograms/h for 2 h, produced a significant increase in urine volume, a significant decrease in urine osmolality, and a significant increase in creatinine clearance. These changes, although less pronounced, persisted 24 h after the infusion of the analogue. No significant changes in free water clearance, urinary sodium excretion or serum sodium were noted. The effects of SMS 201-995 might be attributed to an improvement of renal haemodynamics through inhibition of vasoconstrictor systems acting in cirrhosis. It is concluded that SMS 201-995 may have a role in the treatment of the renal abnormalities complicating liver disease.
Mountokalakis
T
T
Second Medical Department, University of Athens, Hippokration Hospital, Greece.
Kallivretakis
N
N
Mayopoulou-Symvoulidou
D
D
Karvountzis
G
G
Tolis
G
G
D000368:Aged; D001201:Ascites / Q000188:drug therapy / Q000503:physiopathology / Q000652:urine*; D003404:Creatinine / Q000652:urine; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000503:physiopathology / Q000652:urine*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000494:pharmacology* / Q000627:therapeutic use; D009994:Osmolar Concentration; D012079:Renal Circulation / Q000187:drug effects
D003404:Creatinine; D015282:Octreotide